Keyword: Ninlaro

Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.

Takeda's $585 million Chinese revenue for FY2017 was only one-tenth of what it collected from Japan, and buying Shire won't change that soon.

Takeda expects Velcade sales to drop more than 30% this year, but it's hoping newer drugs Ninlanro and Entyvio help fill the gap.

Lilly will close its Shanghai R&D center, OrbiMed sets up its third Asia healthcare fund, and Takeda marches into CAR-T with a new deal.

Takeda's CEO has said Ninlaro would surpass blockbuster Velcade as the company’s biggest-ever cancer product. But NICE could get in the way.

Takeda's blockbuster cancer med Velcade, previously set for copycat competition this year, won an appeals court ruling preserving sales for years.

With a patent loss looming, Takeda filed a citizen petition pushing the FDA to knock back generic Velcade competition.

Nanjing Legend Biotech reported 100% ORR for a CAR-T product, Chi-Med touted fruquintinib's low liver toxicity, Eisai's Lenvima could challenge Bayer's Nexavar and more.

Takeda is starting work on a €40 million plant to manufacture multiple myeloma drug Ninlaro at its site in Ireland, where it will add 40 new jobs.